Genocea Biosciences
100 Acorn Park Drive
Cambridge
Massachusetts
02140
United States
Tel: 617-876-8191
Fax: 617-876-8192
Website: http://www.genocea.com/
Email: website.inquiry@genocea.com
About Genocea Biosciences
Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases.Genocea’s pipeline includes programs addressing genital herpes, pneumococcus, chlamydia, malaria and cancer immunotherapy. We currently have two products in Phase 2 clinical development:
• GEN-003, an immunotherapy to treat patients with genital herpes. We reported positive top-line data from an ongoing Phase 2b dose optimization trial from the immediate post dosing 28-day observation period in May 2015. We identified an improved dose of 60µg per protein/75µg of adjuvant, which demonstrated a highly statistically significant reduction (p>0.0001) from baseline in the viral shedding rate (55%) and genital lesion rate (60%). Data from the six-month and 12-month observation periods in this trial is expected in the fourth quarter of 2015 and the first quarter of 2016, respectively.
Data from the prior Phase 1/2a trial was the first time a therapeutic vaccine candidate has demonstrated significant reductions in the rates of viral shedding and genital lesions in genital herpes patients.
• GEN-004, a universal vaccine which is in Phase 2 development to prevent infections caused by all serotypes of pneumococcus. We have completed enrollment in a Phase 2 human challenge clinical trial and expect to report top-line data in the fourth quarter of 2015.
In a prior Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.
193 articles about Genocea Biosciences
-
Genocea Biosciences Licenses Extensive Herpes Simplex Virus Patent Estate from the University of Washington
2/23/2010
-
Genocea Biosciences Awarded Grant for the Development of Chlamydia Vaccines from the University of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center
12/15/2009
-
Genocea Biosciences Expands Scientific Advisory Board with Appointment of Four Vaccine Experts
11/23/2009
-
BusinessWeek Names Genocea Biosciences One of the World's Most Intriguing Startups
11/16/2009
-
Genocea Biosciences Appoints John Sorvillo Vice President of Business Development
7/28/2009
-
Genocea Biosciences Names Robert E. Farrell, Jr. Vice President, Finance and Administration
6/19/2009
-
Genocea Biosciences Closes $23 Million Series A Financing, Names Vaccine Veteran Staph Leavenworth Bakali CEO
2/19/2009
-
Genocea Biosciences Names Jane Halpern Vice President of Regulatory Affairs
2/11/2009
-
Vaccine Executive Staph Bakali Joins Genocea Biosciences' Board of Directors
7/23/2008
-
Genocea Biosciences Teams with Pneumococcus Expert Richard Malley of Children's Hospital Boston/Harvard Medical School
6/5/2008
-
Genocea Biosciences Wins ''Best Vaccine Startup'' Award at World Vaccine Congress 2008
4/23/2008
-
Genocea Biosciences Licenses Portfolio of Vaccine Targets from Harvard Medical School
12/18/2007
-
Genocea Biosciences Appoints Adel Mahmoud and Robert Finberg to Scientific Advisory Board
8/21/2007